ELSEVIER

Clinica Chimica Acta 264 (1997) 261–263

Author index

Volume 264 (1997)

Abraham-Inpijn, L., see Brand, H.S. **264**, 37
Adam, A., see Sørensen, S.H. **264**, 103
Alataş, F., see Metintaş, M. **264**, 149
Alataş, Ö., see Metintaş, M. **264**, 149
Aubó, C., see Sentí, M. **264**, 193
Aung, W., Kyaw, A., Win, T., Kyaw, K.-P.-P., Hla, B., Hlaing, T.-T., Isoenzyme profile of urinary NAG in Russell's viper bite patients with renal damage **264**, 251

Bahadir, S., see Örem, A. **264**, 49
Batt, R.M., see Sørensen, S.H. **264**, 103
Bergeron, C., see Mathieu, P. **264**, 255
Bernard, H., see Taran, F. **264**, 177
Bory, C., see Mathieu, P. **264**, 255
Bourguignat, A., Férard, G., Jenny, J.-Y., Gaudias, J., Incomplete or absent acute phase response in some postoperative patients **264**, 27
Brand, H.S., Jörning, G.G.A., Chamuleau, R.A.F.M., Abraham-Inpijn, L., Effect of a protein-rich meal on urinary and salivary free amino acid concentrations in human subjects **264**, 37
Brown, J.H., see McGrath, L.T. **264**, 1

Catapano, A.L., see Lambert, D.A. **264**, 75
Chamuleau, R.A.F.M., see Brand, H.S. **264**, 37
Chauvin, F., see Mathieu, P. **264**, 255
Çimşit, G., see Örem, A. **264**, 49
Çolak, Ö., see Metintaş, M. **264**, 149
Créminon, C., see Taran, F. **264**, 177

David, L., see Mathieu, P. **264**, 255
Değer, O., see Örem, A. **264**, 49
Deverre, J.-R., see Taran, F. **264**, 177
Dia, S., see Mathieu, P. **264**, 255
Domján, G., see Vályi-Nagy, I. **264**, 117

Erginel, S., see Metintaş, M. **264**, 149
Estelberger, W., see Reibnegger, G. **264**, 207

Férard, G., see Bourguignat, A. **264**, 27
Fingerhut, R., Stehn, M., Kohlschütter, A., Comparison of four different phenylalanine determination methods **264**, 65
Finotti, P., Pagetta, A., Albumin contamination of a purified human α_1-antitrypsin preparation does not affect either structural conformation or the electrophoretic mobility of the inhibitor **264**, 133
Frappaz, D., see Mathieu, P. **264**, 255
Fujita, K., Immunochemical study of immunoglobulins bound to lactate dehydrogenase **264**, 163

Gaudias, J., see Bourguignat, A. **264**, 27
Gönczöl, É., see Vályi-Nagy, I. **264**, 117
Gotto Jr., A.M., see Lambert, D.A. **264**, 75
Grassi, J., see Taran, F. **264**, 177
Greffe, J., see Mathieu, P. **264**, 255
Gunter, E.W., see Spierto, F.W. **264**, 227

Habbal, Z.M., Sakr, A., Rapid, specific HPLC method for the determination of argininosuccinic acid following pre-column derivatization with *o*-phthaladehyde **264**, 239
Hannon, W.H., see Spierto, F.W. **264**, 227
Hla, B., see Aung, W. **264**, 251
Hlaing, T.-T., see Aung, W. **264**, 251
Huang, X.-H., Koivula, T., Ilveskoski, E., Karhunen, P.J., Rantalaiho, V., Wirta, O., Pasternack, A., Lehtimäki, T., Fast 5-hour determination of angiotensin-converting enzyme genotypes from blood by SDS–PAGE using PhastSystem **264**, 57

0009-8981/97/$17.00 Elsevier Science B.V. All rights reserved
PII S0009-8981(97)00126-5

Ilveskoski, E., see Huang, X.-H. **264**, 57
Isobe, K., see Nomura, F. **264**, 233
Itoga, S., see Nomura, F. **264**, 233
Iwasa, S., see Iwata, S. **264**, 245
Iwata, S., Sukegawa, K., Sasaki, T., Kokuryu, M., Yamasita, S., Noma, A., Iwasa, S., Kondo, N., Orii, T., Mass screening test for mucopolysaccharidoses using the 1,9-dimethylmethylene blue method. Positive interference from paper diapers **264**, 245

Jákó, J.M., see Vályi-Nagy, I. **264**, 117
Jenny, J.-Y., see Bourguignat, A. **264**, 27
Jian Hua, M., Yong Kun, H., Shi Jie, C., Zhi Yun, N., Qing De, W., Yang, Z., Urinary microalbumin and retinol-binding protein assay for verifying children's nephron development and maturation **264**, 127
Jörning, G.G.A., see Brand, H.S. **264**, 37

Kaffka, K.J., see Vályi-Nagy, I. **264**, 117
Karhunen, P.J., see Huang, X.-H. **264**, 57
Kohlschütter, A., see Fingerhut, R. **264**, 65
Koivula, T., see Huang, X.-H. **264**, 57
Kokuryu, M., see Iwata, S. **264**, 245
Kondo, N., see Iwata, S. **264**, 245
Kyaw, A., see Aung, W. **264**, 251
Kyaw, K.-P.-P., see Aung, W. **264**, 251

Lambert, D.A., Catapano, A.L., Smith, L.C., Sparrow, J.T., Gotto Jr., A.M., A new fluorometric method for measuring the action of C apolipoproteins on milk lipoprotein lipase **264**, 75
Lang, T., see Reibnegger, G. **264**, 207
Lehtimäki, T., see Huang, X.-H. **264**, 57
Lijnen, P., Saavedra, A., Petrov, V., In vitro proliferative response of human peripheral blood mononuclear cells to concanavalin A **264**, 91

Markwell, P., see Sørensen, S.H. **264**, 103
Marrugat, J., see Sentí, M. **264**, 193
Martín, S., see Sentí, M. **264**, 193
Mathieu, M., see Mathieu, P. **264**, 255
Mathieu, P., Prevel, A., David, L., Bergeron, C., Bory, C., Chauvin, F., Dia, S., Frappaz, D., Greffe, J., Mathieu, M., Philip, T., Screening infants for neuroblastoma: discovery of alkaptonuria in one case **264**, 255
McClean, E., see McGrath, L.T. **264**, 1
McGrath, L.T., Treacy, R., McClean, E., Brown, J.H., Oxidative stress in cyclosporin and azathioprine treated renal transplant patients **264**, 1
Metintaş, M., Alataş, Ö., Alataş, F., Çolak, Ö., Özdemir, N., Erginel, S., Comparative analysis of biochemical parameters for differentiation of pleural exudates from transudates Light's criteria, cholesterol, bilirubin, albumin gradient, alkaline phosphatase, creatine kinase, and uric acid **264**, 149

Nagasawa, K., see Yoshizawa, S. **264**, 219
Nakai, T., see Nomura, F. **264**, 233
Niho, Y., see Yoshizawa, S. **264**, 219
Noda, M., see Nomura, F. **264**, 233
Noma, A., see Iwata, S. **264**, 245
Nomura, F., Takashima, H., Itoga, S., Isobe, K., Takekoshi, K., Noda, M., Nakai, T., Serum NAD glycohydrolase activities in normal subjects and in patients with chronic liver diseases **264**, 233

Okochi, K., see Yoshizawa, S. **264**, 219
Olichon, D., see Taran, F. **264**, 177
Örem, A., Değer, O., Çimşit, G., Bahadir, S., Plasma polymorphonuclear leukocyte elastase levels and its relation to disease activity in psoriasis **264**, 49
Orii, T., see Iwata, S. **264**, 245
Özdemir, N., see Metintaş, M. **264**, 149

Pagetta, A., see Finotti, P. **264**, 133
Pasternack, A., see Huang, X.-H. **264**, 57
Pavesi, M., see Sentí, M. **264**, 193
Pedro-Botet, J., see Sentí, M. **264**, 193
Pena, A., see Sentí, M. **264**, 193
Petrov, V., see Lijnen, P. **264**, 91
Philip, T., see Mathieu, P. **264**, 255
Pradelles, P., see Taran, F. **264**, 177
Prevel, A., see Mathieu, P. **264**, 255
Proud, F.J., see Sørensen, S.H. **264**, 103

Qing De, W., see Jian Hua, M. **264**, 127

Raghothama, C., Rao, P., Degradation of glycated hemoglobin. Role of erythrocytic proteolytic enzymes and oxidant damage **264**, 13
Rantalaiho, V., see Huang, X.-H. **264**, 57
Rao, P., see Raghothama, C. **264**, 13
Reibnegger, G., Lang, T., Estelberger, W., Information theoretical concepts in clinical chemistry: the use of spreadsheet programs for convenient calculation of information theoretical quantities **264**, 207
Rubiés-Prat, J., see Sentí, M. **264**, 193
Rutgers, H.C., see Sørensen, S.H. **264**, 103

Saavedra, A., see Lijnen, P. **264**, 91
Sakr, A., see Habbal, Z.M. **264**, 239

Sasaki, T., see Iwata, S. **264**, 245
Sentí, M., Pedro-Botet, J., Pavesi, M., Marrugat, J., Aubó, C., Pena, A., Martín, S., Rubiés-Prat, J., Interaction of family history of atherosclerosis with atherogenic lipid traits in men with non-coronary atherosclerosis **264**, 193
Shi Jie, C., see Jian Hua, M. **264**, 127
Smith, L.C., see Lambert, D.A. **264**, 75
Smith, S.J., see Spierto, F.W. **264**, 227
Sørensen, S.H., Proud, F.J., Rutgers, H.C., Markwell, P., Adam, A., Batt, R.M., A blood test for intestinal permeability and function: A new tool for the diagnosis of chronic intestinal disease in dogs **264**, 103
Sparrow, J.T., see Lambert, D.A. **264**, 75
Spierto, F.W., Hannon, W.H., Gunter, E.W., Smith, S.J., Stability of urine creatinine **264**, 227
Stehn, M., see Fingerhut, R. **264**, 65
Sukegawa, K., see Iwata, S. **264**, 245

Takashima, H., see Nomura, F. **264**, 233
Takekoshi, K., see Nomura, F. **264**, 233
Taran, F., Bernard, H., Valleix, A., Créminon, C., Grassi, J., Olichon, D., Deverre, J.-R., Pradelles, P., Competitive enzyme immunoassay for urinary vanillylmandelic acid **264**, 177
Treacy, R., see McGrath, L.T. **264**, 1

Valleix, A., see Taran, F. **264**, 177
Vályi-Nagy, I., Kaffka, K.J., Jákó, J.M., Gönczöl, É., Domján, G., Application of near infrared spectroscopy to the determination of haemoglobin **264**, 117

Win, T., see Aung, W. **264**, 251
Wirta, O., see Huang, X.-H. **264**, 57

Yae, Y., see Yoshizawa, S. **264**, 219
Yamasita, S., see Iwata, S. **264**, 245
Yang, Z., see Jian Hua, M. **264**, 127
Yong Kun, H., see Jian Hua, M. **264**, 127
Yoshizawa, S., Nagasawa, K., Yae, Y., Niho, Y., Okochi, K., A thermolabile β2-macroglycoprotein (TMG) and the antibody against TMG in patients with systemic lupus erythematosus **264**, 219

Zhi Yun, N., see Jian Hua, M. **264**, 127

ELSEVIER

Clinica Chimica Acta 264 (1997) 265–268

Subject index

Volume 264 (1997)

Acute phase response; C-reactive protein; Transthyretin; Open fracture **264**, 27

Alkaptonuria; Neuroblastoma (NB); Vanillylmandelic acid (VMA); Homovanillic acid (HVA); Homogentisic acid **264**, 255

Angiotensin-converting enzyme; Electrophoresis; Genetic polymorphism; Polymerase chain reaction **264**, 57

α_1-Antitrypsin; Serum albumin; Purification; Structural conformation; (Human) **264**, 133

Apolipoproteins; Lipoprotein lipase; Protein cofactors **264**, 75

Argininosuccinic acid; O-phthaladehyde; Urea **264**, 239

Atherosclerosis; lipoproteins; lipoprotein (a); LDL subclasses **264**, 193

Autoantibody; β2-macroglycoprotein; Systemic lupus erythematosus (SLE) **264**, 219

Azathioprine; Oxidative stress; Renal transplantation; Cyclosporin; Free radicals **264**, 1

Blood; Rhamnose; 3-O-methyl-D-glucose; Xylose; Lactulose; HPLC; Glucose elimination **264**, 103

C-reactive protein; Transthyretin; Acute phase response; Open fracture **264**, 27

Catecholamine metabolites; Enzyme immunoassay; Vanillylmandelic acid; Homovanillic acid; Neuroblastoma; Pheochromocytoma **264**, 177

Complex formation; LD–BJP complex; LD–IgG complex; NAD^+ binding site; Tyrosine; β-sheet structure **264**, 163

Computer programs; Test evaluation; Entropy; Uncertainty; Information content; Transinformation **264**, 207

Concanavalin A; Proliferation; Mononuclear cells **264**, 91

Creatinine; Stability; Urine; Temperature; Time **264**, 227

Cyclosporin; Oxidative stress; Renal transplantation; Azathioprine; Free radicals **264**, 1

Development; RBP; MALB; Nephron; Maturation **264**, 127

Diabetes mellitus; Glycated hemoglobin; Oxidant damaged hemoglobin; Erythrocytes; Proteolytic enzymes **264**, 13

1,9-Dimethylmethylene blue; Mucopolysaccharidosis; Mass screening; Glycosaminoglycans **264**, 245

Electrophoresis; Angiotensin-converting enzyme; Genetic polymorphism; Polymerase chain reaction **264**, 57

Entropy; Test evaluation; Uncertainty; Information

0009-8981/97/$17.00 Elsevier Science B.V. All rights reserved
PII S0009-8981(97)00127-7

content; Transinformation; Computer programs **264**, 207

Enzyme immunoassay; Vanillylmandelic acid; Homovanillic acid; Catecholamine metabolites; Neuroblastoma; Pheochromocytoma **264**, 177

Erythrocytes; Glycated hemoglobin; Oxidant damaged hemoglobin; Proteolytic enzymes; Diabetes mellitus **264**, 13

Free radicals; Oxidative stress; Renal transplantation; Cyclosporin; Azathioprine **264**, 1

Genetic polymorphism; Angiotensin-converting enzyme; Electrophoresis; Polymerase chain reaction **264**, 57

Glucose elimination; Rhamnose; 3-O-methyl-D-glucose; Xylose; Lactulose; HPLC; Blood **264**, 103

Glycated hemoglobin; Oxidant damaged hemoglobin; Erythrocytes; Proteolytic enzymes; Diabetes mellitus **264**, 13

Glycosaminoglycans; Mucopolysaccharidosis; 1,9-Dimethylmethylene blue; Mass screening **264**, 245

Haemoglobin concentration; Near infrared (NIR) spectroscopy; Reagentless determination of haemoglobin **264**, 117

Homogentisic acid; Neuroblastoma (NB); Alkaptonuria; Vanillylmandelic acid (VMA); Homovanillic acid (HVA) **264**, 255

Homovanillic acid (HVA); Neuroblastoma (NB); Alkaptonuria; Vanillylmandelic acid (VMA); Homogentisic acid **264**, 255

Homovanillic acid; Enzyme immunoassay; Vanillylmandelic acid; Catecholamine metabolites; Neuroblastoma; Pheochromocytoma **264**, 177

HPLC; Rhamnose; 3-O-methyl-D-glucose; Xylose; Lactulose; Blood; Glucose elimination **264**, 103

(Human); Serum albumin; α_1-Antitrypsin; Purification; Structural conformation **264**, 133

Inflammation; PMN elastase; Psoriasis **264**, 49

Information content; Test evaluation; Entropy; Uncertainty; Transinformation; Computer programs **264**, 207

Isoenzymes; Urinary NAG; Viper; Renal damage **264**, 251

LDL subclasses; Atherosclerosis; lipoproteins; lipoprotein (a) **264**, 193

LD–BJP complex; LD–IgG complex; NAD^+ binding site; Tyrosine; β-sheet structure; Complex formation **264**, 163

LD–IgG complex; LD–BJP complex; NAD^+ binding site; Tyrosine; β-sheet structure; Complex formation **264**, 163

Lactulose; Rhamnose; 3-O-methyl-D-glucose; Xylose; HPLC; Blood; Glucose elimination **264**, 103

Lipoprotein lipase; Apolipoproteins; Protein cofactors **264**, 75

lipoprotein (a); Atherosclerosis; lipoproteins; LDL subclasses **264**, 193

lipoproteins; Atherosclerosis; lipoprotein (a); LDL subclasses **264**, 193

Liver cirrhosis; NAD glycohydrolase **264**, 233

***β*2-macroglycoprotein**; Autoantibody; Systemic lupus erythematosus (SLE) **264**, 219

MALB; RBP; Nephron; Development; Maturation **264**, 127

Mass screening; Mucopolysaccharidosis; 1,9-Dimethylmethylene blue; Glycosaminoglycans **264**, 245

Maturation; RBP; MALB; Nephron; Development **264**, 127

3-O-methyl-D-glucose; Rhamnose; Xylose; Lactulose; HPLC; Blood; Glucose elimination **264**, 103

Mononuclear cells; Concanavalin A; Proliferation **264**, 91

Mucopolysaccharidosis; 1,9-Dimethylmethylene blue; Mass screening; Glycosaminoglycans **264**, 245

NAD glycohydrolase; Liver cirrhosis **264**, 233

NAD^+ binding site; LD–BJP complex; LD–IgG complex; Tyrosine; β-sheet structure; Complex formation **264**, 163

Near infrared (NIR) spectroscopy; Haemoglobin concentration; Reagentless determination of haemoglobin **264**, 117

Nephron; RBP; MALB; Development; Maturation **264**, 127

Neuroblastoma; Enzyme immunoassay; Vanillylmandelic acid; Homovanillic acid; Catecholamine metabolites; Pheochromocytoma **264**, 177

Neuroblastoma (NB); Alkaptonuria; Vanillylmandelic acid (VMA); Homovanillic acid (HVA); Homogentisic acid **264**, 255

New-born screening; Phenylketonuria **264**, 65

O-phthaladehyde; Argininosuccinic acid; Urea **264**, 239

Open fracture; C-reactive protein; Transthyretin; Acute phase response **264**, 27

Oxidant damaged hemoglobin; Glycated hemoglobin; Erythrocytes; Proteolytic enzymes; Diabetes mellitus **264**, 13

Oxidative stress; Renal transplantation; Cyclosporin; Azathioprine; Free radicals **264**, 1

PMN elastase; Inflammation; Psoriasis **264**, 49

Phenylketonuria; New-born screening **264**, 65

Pheochromocytoma; Enzyme immunoassay; Vanillylmandelic acid; Homovanillic acid; Catecholamine metabolites; Neuroblastoma **264**, 177

Plasma; Saliva; Threonine; Urine; Valine **264**, 37

Pleural fluid; Uric acid; Serum cholesterol **264**, 149

Polymerase chain reaction; Angiotensin-converting enzyme; Electrophoresis; Genetic polymorphism **264**, 57

Proliferation; Concanavalin A; Mononuclear cells **264**, 91

Protein cofactors; Apolipoproteins; Lipoprotein lipase **264**, 75

Proteolytic enzymes; Glycated hemoglobin; Oxidant damaged hemoglobin; Erythrocytes; Diabetes mellitus **264**, 13

Psoriasis; PMN elastase; Inflammation **264**, 49

Purification; Serum albumin; α_1-Antitrypsin; Structural conformation; (Human) **264**, 133

RBP; MALB; Nephron; Development; Maturation **264**, 127

Reagentless determination of haemoglobin; Near infrared (NIR) spectroscopy; Haemoglobin concentration **264**, 117

Renal damage; Urinary NAG; Isoenzymes; Viper **264**, 251

Renal transplantation; Oxidative stress; Cyclosporin; Azathioprine; Free radicals **264**, 1

Rhamnose; 3-O-methyl-D-glucose; Xylose; Lactulose; HPLC; Blood; Glucose elimination **264**, 103

Saliva; Plasma; Threonine; Urine; Valine **264**, 37

Serum albumin; α_1-Antitrypsin; Purification; Structural conformation; (Human) **264**, 133

Serum cholesterol; Pleural fluid; Uric acid **264**, 149

β-sheet structure; LD–BJP complex; LD–IgG complex; NAD^+ binding site; Tyrosine; Complex formation **264**, 163

Stability; Creatinine; Urine; Temperature; Time **264**, 227

Structural conformation; Serum albumin; α_1-Antitrypsin; Purification; (Human) **264**, 133

Systemic lupus erythematosus (SLE); Autoantibody; β2-macroglycoprotein **264**, 219

Temperature; Creatinine; Stability; Urine; Time **264**, 227

Test evaluation; Entropy; Uncertainty; Information content; Transinformation; Computer programs **264**, 207

Threonine; Plasma; Saliva; Urine; Valine **264**, 37

Time; Creatinine; Stability; Urine; Temperature **264**, 227

Transinformation; Test evaluation; Entropy; Uncertainty; Information content; Computer programs **264**, 207

Transthyretin; C-reactive protein; Acute phase response; Open fracture **264**, 27

Tyrosine; LD–BJP complex; LD–IgG complex; NAD^+ binding site; β-sheet structure; Complex formation **264**, 163

Uncertainty; Test evaluation; Entropy; Information content; Transinformation; Computer programs **264**, 207

Urea; Argininosuccinic acid; O-phthaladehyde **264**, 239

Uric acid; Pleural fluid; Serum cholesterol **264**, 149

Uric acid; Pleural fluid; Uric acid; Serumcholesterol **264**, 149

Urinary NAG; Isoenzymes; Viper; Renal damage **264**, 251

Urine; Creatinine; Stability; Temperature; Time **264**, 227

Urine; Plasma; Saliva; Threonine; Valine **264**, 37

Valine; Plasma; Saliva; Threonine; Urine **264**, 37

Vanillylmandelic acid (VMA); Neuroblastoma (NB); Alkaptonuria; Homovanillic acid (HVA); Homogentisic acid **264**, 255

Vanillylmandelic acid; Enzyme immunoassay; Homovanillic acid; Catecholamine metabolites; Neuroblastoma; Pheochromocytoma **264**, 177

Viper; Urinary NAG; Isoenzymes; Renal damage **264**, 251

Xylose; Rhamnose; 3-O-methyl-D-glucose; Lactulose; HPLC; Blood; Glucose elimination **264**, 103